SLC5A2 and type 2 diabetes mellitus: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a cornerstone in the treatment of type 2 diabetes mellitus, with robust evidence of additional benefits on cardiovascular and renal outcomes [19].